SCHEMBL6711050

SCHEMBL6711050

Clc1cnc2cc3ccccc3nc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
GLA P06280 2/20 0.52
HPGD P15428 2/20 0.52
MAPT P10636 2/20 0.52
ACHE P22303 1/20 0.52
NQO2 P16083 1/20 0.50
CYP1A2 P05177 1/20 0.46
KDR P35968 1/20 0.43
KMT2A Q03164 2/20 0.42
ALPL P05186 1/20 0.41
PDGFRB P09619 2/20 0.41
PDGFRA P16234 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MGAM O43451 1/20 0.41
NR4A2 P43354 1/20 0.40
HTR3A P46098 1/20 0.40
KDM4E B2RXH2 2/20 0.39
GPR3 P46089 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL438735 0.84 CYP1A2 (0.57) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL2306728 0.82 CYP1A2 (0.55) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL5469928 0.78 MAPT (0.82) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL13156491 0.76 MAPT (0.78) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL29070960 0.76 ALDH1A1 (0.42) ALDH1A1HPGDKMT2APDGFRBPDGFRA
SCHEMBL1008611 0.76 MAPT (0.50) ALDH1A1GLAHPGDMAPTACHE
Phosphoric Acid SCHEMBL28789787 0.74 KDR (0.57) ALDH1A1CYP1A2KDRKMT2AALPL
SCHEMBL18015669 0.74 KDM4E (0.50) ALDH1A1MAPTCYP1A2PDGFRBPDGFRA
SCHEMBL7689829 0.74 ALDH1A1 (0.61) ALDH1A1MAPTNQO2CYP1A2KDR
SCHEMBL17423219 0.74 MAPT (0.65) ALDH1A1GLAHPGDMAPTACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040002498-A1 Tricyclic compounds useful as HIV reverse transcriptase inhibitors JOHNSON BARRY L (US) 2004-01-01 US disclosed
US-6593337-B1 pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent. BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-07-15 US disclosed
EP-1222186-A2 CONDENSED NAPHTHYRIDINES AS HIV REVERSE TRANSCRIPTASE INHIBITORS Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
WO-2001029037-A2 CONDENSED NAPHTHYRIDINES AS HIV REVERSE TRANSCRIPTASE INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002498-A1 Tricyclic compounds useful as HIV reverse transcriptase inhibitors POLRMT, TYMP, POLM ALDH1A1 610/4885GLA 946/4885HPGD 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.